SD230323-078 page 1 of 1

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

sample Forbidden Fruit Diamond Sauce

| 2 dime | | |
|--------|-----------------|------|
| | SD Pharm | Labs |

QA Testing

| Sample ID SD230323-078 (71025) | | Matrix Concentrate (Inhalable Cannabis Good) | |
|-------------------------------------|-----------------------|----------------------------------------------|--|
| Tested for Top Shelf Hemp Co | | | |
| Sampled - | Received Mar 23, 2023 | Reported Mar 24, 2023 | |
| Sampled - Analyses executed CANX | Received Mar 23, 2023 | Reported Mar 24, 2023 | |

Laboratory note: The estimated concentration of the unknown peak in the sample is 2.59% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC (+)d8-THC is a different compound from the main (-)d8-THC canobinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC and d9-THC and d9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 concentration is estimated to be 19.9%.

CANX - Cannabinoids Analysis

Analyzed Mar 24, 2023 | Instrument HLPC The expanded Uncertainty of the Cannabinoid analysis is approximately **3**.806% at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|----------------------------------------------------------------------|-------------|-------------|-------------|----------------|
| 11-Hydroxy-∆8-Tetrahydrocannabivarin (11-Hyd-∆8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiorcin (CBDO) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiorcin (a-CBDO) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-∆8-Tetrahydrocannabinol (11-Hyd-∆8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| 1(S)-THD (s-THD) | 0.013 | 0.041 | ND | ND |
| 1(R)-THD (r-THD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabivarin (Δ8-THCV) | 0.021 | 0.064 | ND | ND |
| Cannabidihexol (CBDH) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabutol (Δ9-THCB) | 0.013 | 0.038 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | ND | ND |
| Cannabidiphorol (CBDP) | 0.015 | 0.047 | ND | ND |
| exo-THC (exo-THC) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | UI | UI |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 19.91 | 199.10 |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | 2.88 | 28.75 |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | 6.53 | 65.32 |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | 61.30 | 613.03 |
| Δ9-Tetrahydrocannabihexol (Δ9-THCH) | 0.024 | 0.071 | ND | ND |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabiphorol (Δ9-THCP) | 0.017 | 0.16 | ND | ND |
| Δ8-Tetrahydrocannabiphorol (Δ8-THCP) | 0.041 | 0.16 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.026 | 0.079 | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.005 | 0.16 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | ND | ND |
| Δ9-THC methyl ether (Δ9-MeO-THC) | | | ND | ND |
| Total THC (THCa * 0.877 + Δ9THC) | | | 53.76 | 537.63 |
| Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC) | | | 73.67 | 736.73 |
| Total CBD (CBDa * 0.877 + CBD) | | | ND | ND |
| Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | 9.41 | 94.08 |
| Total Cannabinoids | | | 83.08 | 830.80 |









Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Fri, 24 Mar 2023 15:35:21 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 "This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fall status is reported, that status is intended to be in accordance with federal, state and local lows which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fall evolution unless explicition unless explicition, state or local lows and has been reported on the retrificate of analysis. Ressurement of uncertainty is available upon request.